Evaluation of the 2-year AVF Utilization Rate

April 21, 2026 updated by: Aurélien Hostalrich, University Paul Sabatier of Toulouse

Evaluation, 2 Years Post-creation, of the AVF Utilization Rate

Arteriovenous fistulas (AVFs) are the standard for dialysis sessions. However, this usually requires surgery before dialysis can begin. Given this pre-operative approach, the investigators evaluate the two-year utilization rate of AVFs and seek to understand why they are still not used in some cases.

Study Overview

Status

Active, not recruiting

Conditions

Intervention / Treatment

Study Type

Observational

Enrollment (Estimated)

1000

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Toulouse, France, 31400
        • Benane Dylan

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Probability Sample

Study Population

Patients for whom the neprhologist indicated an AVF creation

Description

Inclusion Criteria:

  • First AVF creation

Exclusion Criteria:

  • Minor patient
  • AVF already

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Intervention / Treatment
AVF creation non dialysed patient
Procedure: AVF creation as indicated by the nephrologist
AVF are creation in the OR when asked by the nephrologist team

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
AVF utilisation
Time Frame: through study completion, an average of 2 years
AVF puncture
through study completion, an average of 2 years

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

University Paul Sabatier of Toulouse

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

January 1, 2018

Primary Completion (Actual)

January 1, 2026

Study Completion (Estimated)

December 1, 2026

Study Registration Dates

First Submitted

April 14, 2026

First Submitted That Met QC Criteria

April 21, 2026

First Posted (Actual)

April 23, 2026

Study Record Updates

Last Update Posted (Actual)

April 23, 2026

Last Update Submitted That Met QC Criteria

April 21, 2026

Last Verified

January 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • UTIFAV

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Fistulae

Clinical Trials on AVF creation as indicated by the nephrologist

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Algeria

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe